2017
DOI: 10.18632/oncotarget.21154
|View full text |Cite
|
Sign up to set email alerts
|

The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis

Abstract: A common deletion polymorphism of the gene Bcl-2 like protein 11 (BCL2L11, BIM) has been reported to cause tyrosine kinase inhibitors (TKIs) resistance in several malignant tumors. However, the conclusions were not consistent in chronic myeloid leukemia (CML) individuals. In order to obtain a reliable conclusion, we systematically searched PubMed, Embase, Web of Science, Chinese Biomedical Database, and China National Knowledge Infrastructure and performed the meta-analysis. Six published articles contain 760 … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 40 publications
(63 reference statements)
0
1
0
Order By: Relevance
“…Members of the BCL-2 family create hetero-or homodimers and operate as anti-or pro-apoptotic regulators engaged in a wide range of cellular functions (NCBI NIH 2022, July 18 ). A Meta-analysis showed that BIM deletion does not show significant results and is not associated with TKI resistance (Xu et al 2017).…”
Section: Bcl-2-like Protein 11mentioning
confidence: 99%
“…Members of the BCL-2 family create hetero-or homodimers and operate as anti-or pro-apoptotic regulators engaged in a wide range of cellular functions (NCBI NIH 2022, July 18 ). A Meta-analysis showed that BIM deletion does not show significant results and is not associated with TKI resistance (Xu et al 2017).…”
Section: Bcl-2-like Protein 11mentioning
confidence: 99%